These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 28698442)

  • 1. Incidence of Ophthalmic Disorders in Patients Treated with the Antineoplastic Agent S-1.
    Moriya K; Shimizu H; Handa S; Sasaki T; Sasaki Y; Takahashi H; Nakamura S; Yoshida H; Kato Y
    Gan To Kagaku Ryoho; 2017 Jun; 44(6):501-506. PubMed ID: 28698442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Eye Disorders Associated with S-1 Chemotherapy in Gastric Cancer Patients].
    Fujii C; Kimura Y; Makari Y; Mikami J; Fujita J; Kamigaki S; Hayashi H; Yanagishita Y; Yasui Y; Ishizaka T
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):1960-1962. PubMed ID: 28133189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A Retrospective Investigation of Lacrimation in Patients Treated with S-1].
    Okuda Y; Mikame Y; Watano R; Masubuchi M; Nishijima H; Shinada M; Mori M; Fujii H; Sudoh T
    Gan To Kagaku Ryoho; 2018 Feb; 45(2):265-268. PubMed ID: 29483417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The Importance of Medication History Management by Hospital and Community Pharmacists for Oral Anticancer Drug S-1(Tegafur/Gimeracil/Oteracil Potassium)--A Retrospective Study].
    Maeda M; Saito Y; Makino Y; Iwase H; Hayashi Y
    Gan To Kagaku Ryoho; 2016 Jan; 43(1):79-83. PubMed ID: 26809530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Optic lesions in patients with epiphora during S-1 therapy].
    Shibahara H; Kuze S; Kyokane T; Takamizawa J; Nakamura H; Atsumi H
    Gan To Kagaku Ryoho; 2010 Sep; 37(9):1735-9. PubMed ID: 20841937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Corneal epithelial disorder, lacrimal drainage obstruction, and conjunctivitis].
    Kase S
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():490-3. PubMed ID: 25831809
    [No Abstract]   [Full Text] [Related]  

  • 7. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer.
    Kinoshita T; Nashimoto A; Yamamura Y; Okamura T; Sasako M; Sakamoto J; Kojima H; Hiratsuka M; Arai K; Sairenji M; Fukushima N; Kimura H; Nakajima T
    Gastric Cancer; 2004; 7(2):104-9. PubMed ID: 15224197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Three cases of corneal disorders associated with an oral anticancer drug S-1].
    Ito S; Tanaka A
    Nippon Ganka Gakkai Zasshi; 2006 Nov; 110(11):919-23. PubMed ID: 17134039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Investigation of epiphora following S-1 therapy].
    Kitamura H; Miyanaga T; Shin H; Fujita M; Miyazaki M; Yagi D; Ito H; Asaumi Y; Hirano Y; Hayashida Y; Maeda K; Ota K; Hayashi H; Douden K; Hattori M; Hashidume Y; Sasaki T
    Gan To Kagaku Ryoho; 2011 Feb; 38(2):259-62. PubMed ID: 21368490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Clinical Evaluation of Tegafur Gimeracil Oteracil Combined with THP and DDP for Second-Line Treatment of Advanced Cardiac Carcinoma.
    Wang HF; Lv JQ
    Cell Biochem Biophys; 2015 Jul; 72(3):695-9. PubMed ID: 25618173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dacryoendoscopic observation and incidence of canalicular obstruction/stenosis associated with S-1, an oral anticancer drug.
    Sasaki T; Miyashita H; Miyanaga T; Yamamoto K; Sugiyama K
    Jpn J Ophthalmol; 2012 May; 56(3):214-8. PubMed ID: 22411166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors.
    Scheulen ME; Saito K; Hilger RA; Mende B; Zergebel C; Strumberg D
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):753-61. PubMed ID: 22020317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S-1 induces meibomian gland dysfunction.
    Matsumoto Y; Dogru M; Sato EA; Ibrahim OM; Tatematsu Y; Ogawa Y; Tsubota K
    Ophthalmology; 2010 Jun; 117(6):1275.e4-7. PubMed ID: 20522337
    [No Abstract]   [Full Text] [Related]  

  • 14. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil and oteracil potassium) for colorectal cancer.
    Kawahara H; Watanabe K; Ushigome T; Noaki R; Kobayashi S; Yanaga K
    Hepatogastroenterology; 2012; 59(113):134-7. PubMed ID: 22251528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiotherapy concurrent with S-1 and radiotherapy alone for T2N0 glottic carcinoma: a retrospective comparative study.
    Higashino M; Kawata R; Lee K; Nishikawa S; Ichihara S; Uesugi Y
    Auris Nasus Larynx; 2014 Aug; 41(4):364-8. PubMed ID: 24656970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outpatient oral chemotherapy with S-1 for unresectable or distant metastatic head and neck cancer.
    Maeda M; Yamashita T; Matsunobu T; Araki K; Tomifuji M; Shiotani A
    Anticancer Res; 2013 Aug; 33(8):3285-9. PubMed ID: 23898093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary toxicity by a cytotoxic agent, S-1.
    Tada Y; Takiguchi Y; Fujikawa A; Kitamura A; Kurosu K; Hiroshima K; Sakao S; Kasahara Y; Tanabe N; Tatsumi K; Kuriyama T
    Intern Med; 2007; 46(15):1243-6. PubMed ID: 17675777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.
    Koda K; Miyauchi H; Kosugi C; Kaiho T; Takiguchi N; Kobayashi S; Maruyama T; Matsubara H;
    Anticancer Res; 2016 Oct; 36(10):5325-5331. PubMed ID: 27798895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group.
    Ohtsu A; Baba H; Sakata Y; Mitachi Y; Horikoshi N; Sugimachi K; Taguchi T
    Br J Cancer; 2000 Jul; 83(2):141-5. PubMed ID: 10901361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of corneal epithelial lesion and keratoconjunctival pigmentation due to anticancer drug S-1.
    Kobashi H; Kamiya K; Shimizu K
    Jpn J Ophthalmol; 2011 Mar; 55(2):163-5. PubMed ID: 21400063
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.